MedAll
Communities
New

Bridging the gap: Updates in Duchenne Muscular Dystrophy Management

24th Apr 2024
1:00 - 2:30pm (GMT)
24th Apr 2024
1:00 - 2:30pm (GMT)
Hosted on MedAll
Attendance certificate available
Free
ONLINE

Description

This program has been supported by an education grant from Pfizer.

In this education our expert panel present cases and discuss new research, clinical trials, novel therapies and the latest global guidelines for the diagnosis and management of Duchenne Muscular Dystrophy (DMD) with Q&A.

It will focus on early diagnosis of DMD and evidenced based protocols for the treatment of DMD. The education will also explore how geographic and demographic disparities can affect the diagnosis, management and care of patients with DMD and discuss strategies to mitigate these, such as how tools like telehealth can help ensure quality of care.

1.5 AMA PRA Category 1 Credits™ are available for this activity.

This is the second of two sessions on Duchenne Muscular Dystrophy. Attendees are welcome to register for one or both sessions for free.

Learning Objectives

Develop Telehealth Competencies for Optimal Care of Patients with DMD in mixed resource settings:

  • Adapt conventional diagnostic criteria and protocols for effective use in telehealth environments.
  • Establish best practices for remote patient monitoring and follow-up, ensuring continuity of care for DMD patients.

Initiate Evidence-Based Treatment Protocols for DMD:

  • Incorporate current clinical guidelines and emerging research into initial treatment plans for DMD patients.
  • Evaluate and modify treatment protocols regularly, based on patient response and new scientific evidence, to ensure optimal care.

Evaluate and Adapt Systematic Strategies for Early Diagnosis of DMD:

  • Regularly review the effectiveness of implemented screening tools and referral networks through metrics such as time-to-diagnosis and referral rates.
  • Implement feedback loops with specialists to understand bottlenecks or inefficiencies in the referral and diagnosis process, making necessary adjustments.

Who is this course for

This online education program has been designed for healthcare professionals in Latin America, Africa, Asia-Pacific & the Middle East. The content is not available for healthcare professionals in South Korea, Japan, China, New Zealand & Australia. The course provides continuing education for:

✅ Paediatricians

✅ Neurologists

✅ Family Physicians

✅ Physicians

✅ Physician Assistants

✅ Nurse Practitioners

✅ Other Health Professionals

Faculty:

Professor Volker Straub

Professor Straub is the now President of the World Muscle Society and the Deputy Dean and Professor of Medicine and Neuromuscular Genetics at the Institute of Translational and Clinical Research at Newcastle University, UK. He is the Director of the university’s John Walton Muscular Dystrophy Research Centre and wrote his PhD thesis on Duchenne muscular dystrophy (DMD). He is the co-founder of TREAT-NMD, which offers guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases. Professor Straub is also the Principal Investigator for a number of interventional trials in DMD. He recently chaired the European MYO-MRI COST Action to develop applications of MR imaging and spectroscopy techniques in neuromuscular disease and is part of the steering committee of the MRC Centre for neuromuscular diseases.

Professor Alberto Dubrovsky

Alberto Dubrovsky is Professor of Neuroscience and Neurology at the University of Buenos Aires and Director of the Department of Neurology. He is President of the Latin American Society of Neuromuscular Diseases (SOLANE), Past President of the Argentine Neurological Society and a member of the Executive Committee-Research Group of Neuromuscular Diseases of the World Federation of Neurology. He belongs to CINRG (Cooperative International Neuromuscular Research Group), an organization dedicated to DMD research working with hundreds of patients, many of whom have been involved in the research since the early 1990s. He has a strong commitment to education in DMD and has given given a great number of lectures on this subject throughout Latin America.

Professor Rasha El Sherif

Professor El Sharif is a highly regarded doctor of Neurology & Genetic diagnosis of Neuromuscular disorders, with over 15 years specializing in the clinical diagnosis and management of muscular dystrophy. She is a WHO rare disorders Expert panel member, has served as the Director of the Neuromuscular Registry, is a member of the Rare Disease Committee at the Egypt Genome Project and is the Faculty Neurology Module Lead and an expert in rare disorders at NewGiza University School of Medicine. She is the founder of the MYO-CARE National Foundation and Director of the MYO-CARE Neuromuscular Centre and she chairs the Rare Disorders Subcommittee. She also directs the Neuromuscular & Neuro-genetics Unit at EgyptAir Hospital.

Emily Rueben OBE

Emily Rueben, co-founder and CEO of Duchenne UK, has made significant strides in the fight against Duchenne muscular dystrophy (DMD) since her eldest son's diagnosis. An Oxford history graduate and former journalist for Channel 4 News and CNN International, she founded Duchenne Children’s Trust, which later became Duchenne UK. Her advocacy has taken her to major regulatory agencies worldwide, earning recognition in the UK House of Commons and a Points of Light award from the UK Prime Minister. Emily has served on several healthcare advisory councils and was honored with an OBE for her contributions to charity and DMD in 2023.

Faculty, planners, and staff disclosure information

AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.

Volker Straub is or has been on advisory boards for Astellas Gene Therapies, Novartis Gene Therapies, Roche, Entrada, Pfizer, Bayer, Sanofi, Sarepta Therapeutics, Vertex Pharmaceuticals. He received speaker honoraria from Pfizer and Sarepta Therapeutics. He has received research grants from Sarepta Therapeutics and Sanofi.

Alberto Dubrovsky is or has been on advisory boards for PTC, Roche, Sarepta, Biogen, Biomarin, Sanofi, Genzyme, Takeda and Ultragenyx. He has received speaking fees/honoraria from Biogen, Genzyme, Sanofi, Sarepta, PTC and Roche. He has received grants or research funding from Sanofi, Genzyme, PTC & Biogen.

Rasha El Sherif & Emily Rueben have no relevant financial or non-financial interests to disclose.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Accreditation statements

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse Practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Other Health Professionals: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Health Professionals should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries

This continuing education activity is active starting 17 April 2024 and will expire on 17 April 2025. Estimated time to complete this activity: 1.5 hours. For all continuing education and content inquiries, including questions to speaker(s), please contact us at ce@affinityced.com

2794 people are attending this event. Sign up today and join your colleagues at this event.

Speaking at this event

View all

Similar events and on demand videos

 
24th Apr 2024
1:00 - 2:30pm (GMT)
Hosted on MedAll
Attendance certificate available
Free
ONLINE